Trial Profile
A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Caffeine; Granisetron; Midazolam; Omeprazole
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 24 Jun 2020 Results assessing the effect of Adavosertib on pharmacokinetics (PK) of probe substrates for CYP1A2 (caffeine; C), CYP2C19 (omeprazole; O) and CYP3A4 (midazolam; M) presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 22 Mar 2019 Status changed from active, no longer recruiting to completed.